Wall Street PR

Sunshine Biopharma Share Price Skyrockets (SBFM)

Sunshine Biopharma (OTC: SBFM) rose a whopping 53.1% today, closing at a share price of $0.49. Volume of the stock reached 428,704 shares, bypassing its average of 63,836. Sunshine Biopharma has been steadily rallying for over one week before soaring today. With today’s rally, Sunshine Biopharma has gained a total of 100% since June 6, 2012, and the year-to-date share price gain totals 122.73%.

There are several newsletters found promoting the stock of Sunshine Biopharma. For example, Rocka $tocks has promoted Sunshine Bipharma and expects to receive 400,000 Rule 144 Restricted Shares for the dissemination of company information. There are four results listed on stockpromoters.com regarding the stock promotion of Sunshine Biopharma.

According to @pennystock24, both Investor Stock Alerts and Investor Ideas promoted Sunshine Biopharma today.

Here are some headlines of Sunshine Biopharma from the past couple of months:

  • June 26, 2012: Sunshine Biopharma announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line.
  • May 22, 2012: Sunshine Biopharma announced that it has completed the pharmacokinetics studies in live rats for its lead anti-tumor compound, Adva-27a. Pharmacokinetics studies involve the determination of the fate of substances administered to a living organism.
  • April 9, 2012: Sunshine Biopharma announced that it received notification that the United States Patent and Trademark Office had issued a “Notice of Allowance” for the patent application covering its lead anti-tumor compound, Adva-27a.

Sunshine Biopharma, incorporated on August 31, 2006, is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

The company’s lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer.

During the year ended December 31, 2011, the early stage preclinical studies for its lead compound, Adva-27a, were completed. As of December 31, 2011, the company planned to conduct its Phase I clinical trials for Adva-27a.

The company competes with Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.